| Term 
 | Definition 
 
        | Single-membrane organelle present in nearly all eukaryotic cells. It contains peroxidase and catalase.   Most important event: beta-oxidation of long chain fatty acids   alpha, beta, and gamma PPAR endogenous ligand: fatty acids, PG, leukotrienes exogenous: drugs |  | 
        |  | 
        
        | Term 
 
        | Retinoid X Receptor (RXR) |  | Definition 
 
        | Ligands: retinoids   dimerizes with PPAR- doesn't matter which one you activate- either way induce generation of dimers |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | attach to nucleus response element induce production of something requires time (hours) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ligand activated transcription factors upon binding to fatty acids or hypolipidemic drugs (fibrates), PPAR-alpa interacts with RXR and regulates the expression of target genes. These genes are involved in the catabolism of fatty acids--> lipoprotein lipase goes up--> PPAR-alpha: hyperlipidemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | activated by PGs, leukotrienes and anti-diabetic thiazolidinediones (glitazones?-lower sugars) and affects the expression of genes invovled in the storage of the fatty acids and others --> clinically insulin sensitivity goes up PPAR-gamma: diabetes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | PPAR-alpha: hyperlipidemia clofibrate genfibrozil (older) fenofibrate bezafibrate ciprofibrate Effects: down TGs**; down cholesterol (modest); down VLDL; up HDL; up and down LDL |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | fibrate side effects: gall stones; LFT Warning! when combined with statins: elevated rhabdomyolysis displace warfarin from protein binding site |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -glitazone PPAR-gamma: diabetes Troglitazone- withdrawn in 2000 Rosiglitazone Pioglitazone improves glycaemic control in people with Type 2 diabetes by inproving insulin sensitivity throught its action at PPAR-γ, and affects lipid metabolism through action at PPAR-γ increase glucose transporters; lowered free fatty acids; enhanced insulin signalling; reduced TNFa; remodeling of adipose tissue --> reducing insulin resistance do not cause hypoglycemia advantage over SU & repaglinide - slow in onset (2-6) weeks   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | monotherapy at does of 45 mg/day over 26 weeks = 2.6% reduction in HbA1c compared to placebo |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | hemoglobin is a protein in RBCs that carries O2. Hemogloin picks up glucose from the bloodstream, becoming "glycated" As blood glucose rises, so does the level of glycated hemoglobin. Once hemoglobin becomes glycated, it remains that way for the life of the RBC, which is 3-4 months. This means the HbA1c test can provide a pictures of your glucose control over several months. ** want under 7 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | hepatic toxicity edema not responding to diuretics increased circulating volume heart failure weight gain paresthesias elevations of creatinine phophokinase (CPK) Might: extensive hepatic metabolism reinstate ovulation in post-menopausal women decrease steroid levels: loss of contraceptive effect |  | 
        |  |